Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TBPH?
Source: PRnewswire
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.950
Low
13.00
Averages
28.40
High
42.00
Current: 18.950
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
See More
Theravance Biopharma's CYPRESS Study Fails to Meet Primary Endpoint
- CYPRESS Study Results: Theravance Biopharma's CYPRESS study did not meet its primary endpoint, the OHSA composite score, leading to the decision to wind down the ampreloxetine program, which significantly impacts the company's future R&D direction and market competitiveness.
- Organizational Restructuring: The company plans to reduce operating costs by approximately 60%, expecting annual savings of about $70 million, which will affect around 50% of the workforce, aiming to optimize resource allocation to support the growth of YUPELRI® in the market.
- Financial Outlook: The company anticipates cash reserves of approximately $400 million by the end of Q1 2026, and combined with ongoing sales from YUPELRI®, expects to generate annualized cash flow of $60 to $70 million, enhancing financial stability.
- Accelerated Strategic Review: Theravance's Strategic Review Committee is expediting the evaluation of various strategic alternatives to maximize shareholder value, including a potential sale of the company, demonstrating the company's adaptability in the face of challenges and commitment to shareholder interests.
See More
Irenic Capital Reduces Stake in Papa John's International
- Share Reduction Scale: Irenic Capital Management reduced its stake in Papa John's International by 748,592 shares, leaving a remaining holding of 325,108 shares valued at $12.51 million, indicating a waning confidence in the company.
- Declining Ownership Proportion: Following this reduction, Papa John's now represents only 0.8% of Irenic's assets under management, removing it from the fund's top five holdings, which reflects a significant shift in investment strategy.
- Poor Performance: Over the past year, Papa John's shares have declined by 30.7%, while the S&P 500 index has returned 16.4%, highlighting the company's lack of competitiveness in the market, which may affect future investor confidence.
- Same-Store Sales Decline: The company's same-store sales in North America fell by 2.7% in the third quarter, indicating sales challenges, prompting investors to closely monitor the upcoming fourth-quarter earnings report on February 26 for future outlook assessment.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
- Clinical Trial Setback: Theravance Biopharma's CYPRESS study failed to meet its primary endpoint, leading to the termination of the ampreloxetine program, which disappointed both patients and employees and significantly impacts the company's future R&D direction.
- Accelerated Strategic Review: The Strategic Review Committee of the Board is expediting its evaluation of various value-maximizing strategic alternatives, including a potential sale of the company, in response to the ampreloxetine program's failure and to enhance shareholder value.
- Organizational Restructuring: The company plans to undergo an organizational restructuring that will cut approximately 50% of its workforce and completely wind down the R&D function, which is expected to reduce operating expenses by about 60%, allowing a sharper focus on the commercialization of YUPELRI®.
- Cash Flow Projections: Following the restructuring, Theravance Biopharma anticipates generating approximately $60 to $70 million in annualized cash flow starting in Q3 2026, providing a stable financial foundation to support future operations and growth.
See More
Theravance Biopharma's CYPRESS Study Fails to Meet Primary Endpoint
- CYPRESS Study Results: Theravance Biopharma's CYPRESS study did not meet its primary endpoint, the OHSA composite score, leading to the decision to wind down the ampreloxetine program, which significantly impacts the company's future R&D direction and market competitiveness.
- Organizational Restructuring: The company plans to reduce operating costs by approximately 60%, expecting annual savings of about $70 million, which will affect around 50% of the workforce, aiming to optimize resource allocation to support the growth of YUPELRI® in the market.
- Financial Outlook: The company anticipates cash reserves of approximately $400 million by the end of Q1 2026, and combined with ongoing sales from YUPELRI®, expects to generate annualized cash flow of $60 to $70 million, enhancing financial stability.
- Accelerated Strategic Review: Theravance's Strategic Review Committee is expediting the evaluation of various strategic alternatives to maximize shareholder value, including a potential sale of the company, demonstrating the company's adaptability in the face of challenges and commitment to shareholder interests.
See More
Irenic Capital Reduces Stake in Papa John's International
- Share Reduction Scale: Irenic Capital Management reduced its stake in Papa John's International by 748,592 shares, leaving a remaining holding of 325,108 shares valued at $12.51 million, indicating a waning confidence in the company.
- Declining Ownership Proportion: Following this reduction, Papa John's now represents only 0.8% of Irenic's assets under management, removing it from the fund's top five holdings, which reflects a significant shift in investment strategy.
- Poor Performance: Over the past year, Papa John's shares have declined by 30.7%, while the S&P 500 index has returned 16.4%, highlighting the company's lack of competitiveness in the market, which may affect future investor confidence.
- Same-Store Sales Decline: The company's same-store sales in North America fell by 2.7% in the third quarter, indicating sales challenges, prompting investors to closely monitor the upcoming fourth-quarter earnings report on February 26 for future outlook assessment.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
